Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Lexicon Genetics, Inc. (NasdaqNM:LEXG)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug  7Earnings Announcement
Location
4000 Research Forest Drive
The Woodlands, TX 77381
Phone: (281) 364-0100
Fax: (281) 296-0749
Email: jwolford@lexgen.com
Employees (last reported count): 322
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 58%
·Over the last 6 months:
 · 4 insider buys; 231.0K shares (0.8% of insider shares)
 · 2 insider sells; 15.0K shares
·Institutional: 30% (71% of float)
(138 institutions)
·Net Inst. Buying: 4.55M shares (+22.80%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Lexicon Genetics, Inc. is a drug discovery company that uses gene knockout technology to define the functions of genes for the discovery of pharmaceutical products. The Company uses its gene-targeting and gene-trapping technologies to generate alterations that selectively disrupt or conditionally regulate the function of the targeted gene. As of December 31, 2000, Lexicon's OmniBank library contained gene knockout clones for more than 40% of all genes in the mammalian genome. The LexVision technology platform of the Company enables it to assess the phenotypic consequences, or function in a living mammal, of the knocked-out gene across a variety of parameters relevant to human disease, including cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and obesity.
More from Market Guide: Expanded Business Description

Financial Summary
LEXG is a genomics company using gene trapping technology to discover thousands of genes and to expand its OmniBank library of tens of thousands of knockout mouse clones for drug discovery. For the six months ended 6/30/01, revenues increased 15% to $6.8 million. Net loss increased 5% to $17.9 million. Revenues reflect increased subscription and license fees. Net loss reflects increased R&D expenses due to higher personnel costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

C. Thomas Caskey, M.D., 62
Chairman
--  --  
Arthur Sands, M.D., Ph.D., 39
Pres, CEO, Director
$525K--  
Julia Gregory, 48
Exec. VP, CFO
272K$439K
Jeffrey Wade, J.D., 36
Exec. VP, Gen. Counsel
259K29K
James Piggott, Ph.D., 46
Sr. VP of Pharmaceutical Biology
249K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:LEXGAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$5.406
Recent Price$9.15 
52-Week High
on 8-Sep-2000
$44.50 
Daily Volume (3-month avg)242.4K
Daily Volume (10-day avg)108.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-75.5%
52-Week Change
relative to S&P500
-67.2%
Share-Related Items
Market Capitalization$474.4M
Shares Outstanding51.8M
Float21.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.00 
Earnings (ttm)-$0.56 
Earnings (mrq)-$0.20 
Sales (ttm)$0.32 
Cash (mrq)$3.76 
Valuation Ratios
Price/Book (mrq)2.29 
Price/EarningsN/A 
Price/Sales (ttm)28.65 
Income Statements
Sales (ttm)$15.3M
EBITDA (ttm)-$24.1M
Income available to common (ttm)-$27.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-12.27%
Return on Equity (ttm)-13.14%
Financial Strength
Current Ratio (mrq)9.49 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$183.8M
Short Interest
As of 8-Aug-2001
Shares Short756.0K
Percent of Float3.5%
Shares Short
(Prior Month)
924.0K
Short Ratio3.92 
Daily Volume193.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.